Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eamonn S Molloy

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Cleveland Clinic Journal of Medicine|November 30, 2011
PML and rheumatology: the contribution of disease and drugsEamonn S Molloy
Rheumatology (Oxford, England)|February 20, 2016
The role of toll like receptors in giant cell arteritisLorraine O'Neill, Eamonn S Molloy
Arthritis Care & Research|September 22, 2020
Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et alRichard Conway, Eamonn S Molloy
Annals of the Rheumatic Diseases|July 17, 2016
Response to: 'Biologic agents for giant cell arteritis: treat to target' by Moiseev et alRichard Conway, Eamonn S Molloy
Current Opinion in Rheumatology|February 8, 2006
Basic calcium phosphate crystals: pathways to joint degenerationEamonn S Molloy, Geraldine M McCarthy
Nature Reviews. Rheumatology|August 4, 2009
Therapy: Targeted but not trouble-free: efalizumab and PMLEamonn S Molloy, Leonard H Calabrese
Nature Clinical Practice. Rheumatology|November 14, 2007
Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis?Eamonn S Molloy, Carol A Langford
Current Rheumatology Reports|May 12, 2004
How crystals damage tissueEamonn S Molloy, Geraldine M McCarthy
Rheumatic Diseases Clinics of North America|March 1, 2006
Advances in the treatment of small vessel vasculitisEamonn S Molloy, Carol A Langford
Autoimmunity Reviews|August 14, 2008
Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?Eamonn S Molloy, Leonard H Calabrese
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Cleveland Clinic Journal of Medicine|November 30, 2011
PML and rheumatology: the contribution of disease and drugsEamonn S Molloy
Rheumatology (Oxford, England)|February 20, 2016
The role of toll like receptors in giant cell arteritisLorraine O'Neill, Eamonn S Molloy
Arthritis Care & Research|September 22, 2020
Ustekinumab in Giant Cell Arteritis: Comment on the Article by Matza et alRichard Conway, Eamonn S Molloy
Annals of the Rheumatic Diseases|July 17, 2016
Response to: 'Biologic agents for giant cell arteritis: treat to target' by Moiseev et alRichard Conway, Eamonn S Molloy
Current Opinion in Rheumatology|February 8, 2006
Basic calcium phosphate crystals: pathways to joint degenerationEamonn S Molloy, Geraldine M McCarthy
Nature Reviews. Rheumatology|August 4, 2009
Therapy: Targeted but not trouble-free: efalizumab and PMLEamonn S Molloy, Leonard H Calabrese
Nature Clinical Practice. Rheumatology|November 14, 2007
Does the dose of methotrexate influence the rate of relapse in patients with Wegener's granulomatosis?Eamonn S Molloy, Carol A Langford
Current Rheumatology Reports|May 12, 2004
How crystals damage tissueEamonn S Molloy, Geraldine M McCarthy
Rheumatic Diseases Clinics of North America|March 1, 2006
Advances in the treatment of small vessel vasculitisEamonn S Molloy, Carol A Langford
Autoimmunity Reviews|August 14, 2008
Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?Eamonn S Molloy, Leonard H Calabrese
Pageof 5